PCVX

Vaxcyte, Inc.

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains, including newly emerging strains responsible for IPD and antibiotic resistance; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease.

Vaxcyte, Inc. (PCVX) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Profitability (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
B+
Factor Score 3.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -9.6
EV / EBITDA -7.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 5.2%
Price Return 12M 37.5%
Catalyst Signal 0.00
Market Cap $10.0B
TTM Revenue N/A
Price / Sales N/A
ROE -42.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C- (2.1) C- (2.0) B+ (3.6) C+ (2.6) C+ (2.6)
2026-11-07 C+ (2.5) C- (2.0) C- (2.0) B+ (3.7) C+ (2.7) C+ (2.6)
2026-10-31 C+ (2.5) C- (2.0) C- (2.1) B (3.2) C+ (2.7) C (2.5)
2026-10-24 C+ (2.5) C- (2.0) C- (2.1) B- (2.9) C+ (2.6) C (2.4)
2026-10-17 C+ (2.5) C- (2.0) C- (2.1) B- (3.1) C+ (2.6) C (2.4)
Page 1 of 3